Clinical Trial Update: Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

View source ↗

Summary

The completed clinical trial evaluated florbetapir as a PET imaging agent in Primary Progressive Aphasia and related dementias, including Alzheimer's disease, t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Progressive Aphasia

Drugs mentioned

• AMYVID (Florbetapir F-18)

Snippet

Sponsor: University of Chicago | Conditions: Primary Progressive Aphasia, Alzheimer Disease | Status: COMPLETED